225 related articles for article (PubMed ID: 34489549)
21. Activating CD137 Signaling Promotes Sprouting Angiogenesis via Increased VEGFA Secretion and the VEGFR2/Akt/eNOS Pathway.
Li B; Zhang Y; Yin R; Zhong W; Chen R; Yan J
Mediators Inflamm; 2020; 2020():1649453. PubMed ID: 33162828
[TBL] [Abstract][Full Text] [Related]
22. LncRNA NEAT1 enhances the resistance of anaplastic thyroid carcinoma cells to cisplatin by sponging miR‑9‑5p and regulating SPAG9 expression.
Yan P; Su Z; Zhang Z; Gao T
Int J Oncol; 2019 Nov; 55(5):988-1002. PubMed ID: 31485599
[TBL] [Abstract][Full Text] [Related]
23. Integrated Bioinformatics Analysis of Master Regulators in Anaplastic Thyroid Carcinoma.
Pan Z; Li L; Fang Q; Qian Y; Zhang Y; Zhu J; Ge M; Huang P
Biomed Res Int; 2019; 2019():9734576. PubMed ID: 31183379
[TBL] [Abstract][Full Text] [Related]
24. VEGF165b Modulates Endothelial VEGFR1-STAT3 Signaling Pathway and Angiogenesis in Human and Experimental Peripheral Arterial Disease.
Ganta VC; Choi M; Kutateladze A; Annex BH
Circ Res; 2017 Jan; 120(2):282-295. PubMed ID: 27974423
[TBL] [Abstract][Full Text] [Related]
25. Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma.
Milosevic Z; Pesic M; Stankovic T; Dinic J; Milovanovic Z; Stojsic J; Dzodic R; Tanic N; Bankovic J
Transl Res; 2014 Nov; 164(5):411-23. PubMed ID: 25016932
[TBL] [Abstract][Full Text] [Related]
26. Thyroid Follicular Cell Loss of Differentiation Induced by MicroRNA miR-17-92 Cluster Is Attenuated by CRISPR/Cas9n Gene Silencing in Anaplastic Thyroid Cancer.
Fuziwara CS; Saito KC; Kimura ET
Thyroid; 2020 Jan; 30(1):81-94. PubMed ID: 31578932
[No Abstract] [Full Text] [Related]
27. Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo.
Szabo E; Schneider H; Seystahl K; Rushing EJ; Herting F; Weidner KM; Weller M
Neuro Oncol; 2016 Sep; 18(9):1242-52. PubMed ID: 27009237
[TBL] [Abstract][Full Text] [Related]
28. SRY‑related HMG box‑2 role in anaplastic thyroid cancer aggressiveness is related to the fibronectin 1 and PI3K/AKT pathway.
Wang P; Shang J; Zhao J; Wang K; Guo L; Gu J; Wang W
Mol Med Rep; 2020 Mar; 21(3):1201-1207. PubMed ID: 31922212
[TBL] [Abstract][Full Text] [Related]
29. Diallyl trisulphide, a H
Zhang L; Xu S; Cheng X; Zheng J; Wang Y; Wu J; Wang X; Wu L; Yu H; Bao J
Phytother Res; 2021 Jun; 35(6):3428-3443. PubMed ID: 33751676
[TBL] [Abstract][Full Text] [Related]
30. Genomic amplification of long noncoding RNA HOTAIRM1 drives anaplastic thyroid cancer progression via repressing miR-144 biogenesis.
Zhang L; Zhang J; Li S; Zhang Y; Liu Y; Dong J; Zhao W; Yu B; Wang H; Liu J
RNA Biol; 2021 Apr; 18(4):547-562. PubMed ID: 32951513
[TBL] [Abstract][Full Text] [Related]
31. FOXD3 regulates anaplastic thyroid cancer progression.
Yin H; Meng T; Zhou L; Zhao F; Li X; Li Y; Hu M; Chen H; Song D
Oncotarget; 2017 May; 8(20):33644-33651. PubMed ID: 28430585
[TBL] [Abstract][Full Text] [Related]
32. ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway.
Zhang Q; Lu S; Li T; Yu L; Zhang Y; Zeng H; Qian X; Bi J; Lin Y
J Exp Clin Cancer Res; 2019 Apr; 38(1):173. PubMed ID: 31023337
[TBL] [Abstract][Full Text] [Related]
33. Targeted inhibition of long non-coding RNA H19 blocks anaplastic thyroid carcinoma growth and metastasis.
Zhang H; Yu Y; Zhang K; Liu X; Dai Y; Jiao X
Bioengineered; 2019 Dec; 10(1):306-315. PubMed ID: 31299871
[TBL] [Abstract][Full Text] [Related]
34. Circular RNA MYLK as a competing endogenous RNA promotes bladder cancer progression through modulating VEGFA/VEGFR2 signaling pathway.
Zhong Z; Huang M; Lv M; He Y; Duan C; Zhang L; Chen J
Cancer Lett; 2017 Sep; 403():305-317. PubMed ID: 28687357
[TBL] [Abstract][Full Text] [Related]
35. The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis.
Liang J; Jin Z; Kuang J; Feng H; Zhao Q; Yang Z; Zhan L; Shen B; Yan J; Cai W; Cheng X; Qiu W
Br J Cancer; 2021 Aug; 125(3):390-401. PubMed ID: 34088989
[TBL] [Abstract][Full Text] [Related]
36. Novel role of ASH1L histone methyltransferase in anaplastic thyroid carcinoma.
Xu B; Qin T; Yu J; Giordano TJ; Sartor MA; Koenig RJ
J Biol Chem; 2020 Jun; 295(26):8834-8845. PubMed ID: 32398261
[TBL] [Abstract][Full Text] [Related]
37. ARL13B promotes angiogenesis and glioma growth by activating VEGFA-VEGFR2 signaling.
Chen L; Xie X; Wang T; Xu L; Zhai Z; Wu H; Deng L; Lu Q; Chen Z; Yang X; Lu H; Chen YG; Luo S
Neuro Oncol; 2023 May; 25(5):871-885. PubMed ID: 36322624
[TBL] [Abstract][Full Text] [Related]
38. Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.
Zhu X; Park S; Lee WK; Cheng SY
Endocr Relat Cancer; 2019 Sep; 26(9):739-750. PubMed ID: 31272080
[TBL] [Abstract][Full Text] [Related]
39. STAT3 signaling statuses determine the fate of resveratrol-treated anaplastic thyroid cancer cells.
Wu J; Li YT; Tian XT; Liu YS; Wu ML; Li PN; Liu J
Cancer Biomark; 2020; 27(4):461-469. PubMed ID: 31958078
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA 483-3p targets Pard3 to potentiate TGF-β1-induced cell migration, invasion, and epithelial-mesenchymal transition in anaplastic thyroid cancer cells.
Zhang X; Liu L; Deng X; Li D; Cai H; Ma Y; Jia C; Wu B; Fan Y; Lv Z
Oncogene; 2019 Jan; 38(5):699-715. PubMed ID: 30171257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
